UBS raised the firm’s price target on Neurocrine to $193 from $174 and keeps a Buy rating on the shares. UBS sees Neurocrine as an attractive stock set-up, with its base business Ingrezza growing strong, the crinecerfont launch in 2025 that can be solid right out of gates, and two major schizophrenia pipeline read-outs in Q3, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- RBC still sees gradual uptake for Neurocrine after competitor data
- Neurocrine competitive data should be kept in perspective, says Evercore
- Neurocrine announces publication of data from Phase 3 KINECT-4 study of INGREZZA
- Neurocrine presents baseline data of CAH program
- Neurocrine initiated with an Outperform at Evercore ISI